Factors determining penetrance in familial atypical haemolytic uraemic syndrome

被引:25
|
作者
Sansbury, Francis H. [1 ,2 ,3 ]
Cordell, Heather J. [4 ]
Bingham, Coralie [2 ,5 ]
Bromilow, Gilly [1 ]
Nicholls, Anthony [5 ]
Powell, Roy [6 ]
Shields, Bev [2 ]
Smyth, Lucy [5 ]
Warwicker, Paul [7 ]
Strain, Lisa [8 ]
Wilson, Valerie [8 ]
Goodship, Judith A. [4 ]
Goodship, Timothy H. J. [4 ]
Turnpenny, Peter D. [1 ,2 ]
机构
[1] Royal Devon & Exeter Hosp Heavitree, Royal Devon & Exeter NHS Fdn Trust, Peninsula Clin Genet Serv, Exeter, Devon, England
[2] Univ Exeter, Sch Med, Exeter, Devon, England
[3] St Michaels Hosp, Univ Hosp Bristol NHS Fdn Trust, Bristol Clin Genet Serv, Bristol, Avon, England
[4] Newcastle Univ, Inst Med Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England
[5] Royal Devon & Exeter Hosp Wonford, Royal Devon & Exeter NHS Fdn Trust, Dept Renal Med, Exeter, Devon, England
[6] Royal Devon & Exeter Hosp Wonford, Royal Devon & Exeter NHS Fdn Trust, Res Design Serv South West, Exeter, Devon, England
[7] East & North Hertfordshire NHS Trust, Lister Renal Units, Stevenage, Herts, England
[8] Newcastle Upon Tyne Hosp NHS Fdn Trust, Northern Mol Genet Serv, Newcastle Upon Tyne, Tyne & Wear, England
基金
英国医学研究理事会;
关键词
COMPLEMENT FACTOR-H; MULTILOCUS LINKAGE ANALYSIS; MEMBRANE COFACTOR PROTEIN; GENE-MUTATIONS; DISEASE; RECOGNITION; CFH; SUSCEPTIBILITY; PREDISPOSE; CANCER;
D O I
10.1136/jmedgenet-2014-102498
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background Inherited abnormalities of complement are found in similar to 60% of patients with atypical haemolytic uraemic syndrome (aHUS). Such abnormalities are not fully penetrant. In this study, we have estimated the penetrance of the disease in three families with a CFH mutation (c.3643C>G; p. Arg1215Gly) in whom a common lineage is probable. 25 individuals have been affected with aHUS with three peaks of incidence-early childhood (n=6), early adulthood (n= 11) and late adulthood (n= 8). Eighteen individuals who have not developed aHUS carry the mutation. Methods We estimated penetrance at the ages of 4, 27, 60 and 70 years as both a binary and a survival trait using MLINK and Mendel. We genotyped susceptibility factors in CFH, CD46 and CFHR1 in affected and unaffected carriers. Results and Conclusions We found that the estimates of penetrance at the age of 4 years ranged from <0.01 to 0.10, at the age of 27 years from 0.16 to 0.29, at the age of 60 years from 0.39 to 0.51 and at the age of 70 years from 0.44 to 0.64. We found that the CFH haplotype on the allele not carrying the CFH mutation had a significant effect on disease penetrance. In this family, we did not find that the CD46 haplotypes had a significant effect on penetrance.
引用
收藏
页码:756 / 764
页数:9
相关论文
共 50 条
  • [31] Atypical haemolytic uraemic syndrome and mutations in complement regulator genes
    Dragon-Durey, MA
    Frémeaux-Bacchi, V
    SPRINGER SEMINARS IN IMMUNOPATHOLOGY, 2005, 27 (03): : 359 - 374
  • [32] Eculizumab: A Review of Its Use in Atypical Haemolytic Uraemic Syndrome
    Keating, Gillian M.
    DRUGS, 2013, 73 (18) : 2053 - 2066
  • [33] Patient stratification and therapy in atypical haemolytic uraemic syndrome (aHUS)
    Wong, Edwin
    Challis, Rachel
    Sheerin, Neil
    Johnson, Sally
    Kavanagh, David
    Goodship, Timothy H. J.
    IMMUNOBIOLOGY, 2016, 221 (06) : 715 - 718
  • [34] Atypical haemolytic uraemic syndrome and mutations in complement regulator genes
    Marie-Agnès Dragon-Durey
    Véronique Frémeaux-Bacchi
    Springer Seminars in Immunopathology, 2005, 27 : 359 - 374
  • [35] A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)
    Rathbone, John
    Kaltenthaler, Eva
    Richards, Anna
    Tappenden, Paul
    Bessey, Alice
    Cantrell, Anna
    BMJ OPEN, 2013, 3 (11):
  • [36] A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome
    Westra, D.
    Wetzels, J. F. M.
    Volokhina, E. B.
    van den Heuvel, L. P.
    van de Kar, N. C. A. J.
    NETHERLANDS JOURNAL OF MEDICINE, 2012, 70 (03): : 121 - 129
  • [37] Atypical haemolytic uraemic syndrome: a case of rare genetic mutation
    Sangeetha, Geminiganesan
    Jayaraj, Jaippreetha
    Ganesan, Swathi
    Puttagunta, Sreeapoorva
    BMJ CASE REPORTS, 2021, 14 (07)
  • [38] Eculizumab: A Review of Its Use in Atypical Haemolytic Uraemic Syndrome
    Gillian M. Keating
    Drugs, 2013, 73 : 2053 - 2066
  • [39] Factor I autoantibodies are associated with atypical haemolytic uraemic syndrome
    Kavanagh, David
    Pappworth, Isabel Y.
    Roversi, Pietro
    Tapson, John S.
    Moore, Iain
    Strain, Lisa
    Lea, Susan
    Goodship, Timothy H. J.
    Marchbank, Kevin J.
    MOLECULAR IMMUNOLOGY, 2010, 47 (13) : 2291 - 2292
  • [40] SYSTEMIC LUPUS ERYTHEMATOSUS MASQUERADING AS ATYPICAL HAEMOLYTIC URAEMIC SYNDROME
    Kuo, S.
    Graver, A.
    Kirkland, G.
    Yu, R.
    NEPHROLOGY, 2017, 22 : 64 - 64